Emerging Biomarker of Kidney Disease: suPAR or Subpar?

Kidney disease is a major contributor to morbidity and mortality in the US, affecting 14% of the population. It is often referred to as a “silent epidemic” because the disease is often asymptomatic until the late stages and current clinical assays only detect it after a substantial portion of kidney capacity has been lost. As such, there is marked interest in kidney disease biomarkers that could identify the extent of kidney damage earlier in...